FROSTPHARMA ENTERS AGREEMENT WITH ADVICENNE FOR MARKETING AND DISTRIBUTION OF SIBNYAL® IN THE NORDIC

FrostPharma AB announces signature of an exclusive Distribution Agreement with Advicenne for marketing and distribution of Sibnayal® in Denmark, Finland, Norway, Iceland and Sweden. Under the terms of the agreement, FrostPharma will receive the exclusive rights to distribute and market Sibnayal® for the treatment of distal renal tubular acidosis (dRTA) in the Nordic countries including Denmark, Finland, Norway, Iceland and Sweden. Sibnayal® received marketing authorisation in the European Union in May 2021 as the first and only label-approved drug for the treatment of Distal Renal Tubular Acidosis (dRTA) in adults, adolescents, and children aged one year and older. Clas Lindbergson, Head of Business Development of FrostPharma stated: “We are proud to be partnering with Advicenne for the delivery of Sibnayal™ to patients and improve the lives of those suffering from Distal Renal Tubular Acidosis (dRTA). We look forward to working with them and to be continuing to expand our product portfolio in areas of high unmet need.” Didier Laurens, Chief Executive Officer of Advicenne, commented: “We are delighted to be partnering with FrostPharma, a leader in the commercialization of a broad range of products across many disease areas. This is Advicenne’s third partnership for the commercialization of Sibnayal™ in just over a few weeks and is testament of our Company’s momentum. We have found in FrostPharma a partner that shares our same goal: delivering life-changing treatments for patients in areas of huge unmet need and we are looking forward to working together.” About FrostPharma FrostPharma is an entrepreneurial Swedish pharmaceutical company specializing in the commercialization of value-added products. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, throughout the Nordic countries and beyond. The key to our success is using our extensive in-house commercialization competence to match specific patient and health care needs with relevant products. For further information about FrostPharma, please visit www.frostpharma.com About Advicenne Advicenne (Euronext: ADVIC) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product SibnayalTM (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US. Headquartered in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019. For additional information see: https://advicenne.com/ CONTACTS FrostPharma AB Clas Lindbergson, Head of Business Development Phone: +46 706 581180  Email: clas.lindbergson@frostpharma.com

FrostPharma organisation announcement

During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. The Regulatory framework and the Commercial capabilities have been strengthened and FrostPharma is now in a position to leverage and maximise its pipe-line opportunities. Cecilia Bröms-Thell has however recently decided to explore new opportunities outside of FrostPharma why she has resigned as CEO. For a period of time Cecilia has however agreed to stay on as Chief Commercial Officer effective 1 january 2022. In this new role Cecilia Bröms-Thell will continue to strengthen the FrostPharma capabilities. “On behalf of FrostPharma and the Board I want to thank Cecilia Bröms-Thell for her significant contribution to the FrostPharma business as CEO and wish her good luck in her new role within FrostPharma as Chief Commercial Officer and later in her new role outside of Frost.” From the 1st of January 2022 Fredrik Andersch take the role of FrostPharma CEO. Fredrik Andersch brings extensive international experience to FrostPharma from senior business positions at pharmaceutical companies such as AstraZeneca and Meda. Fredrik Andersch has a proven track-record of delivering strong growth through complex organisations both in a Nordic and international setting, such as Europe and Asia. With his background Fredrik Andersch also strengthen FrostPharma business development capabilities. The experience to drive growth through both portfolio and geographic expansion will further strengthen FrostPharma in its growth journey. As Fredrik consulted for FrostPharma in 2021 he has in-depth understanding of the organisation and business model, which secure business continuity during the transition. “On behalf of FrostPharma and the Board I want to wish Fredrik Andersch good luck in his role of CEO, and I look forward to working with him going forward.” About Frost Pharma AB FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence. Tomas Guinchard Chairman of the Board

FrostPharma wins two national tenders in Norway

FrostPharma is proud and pleased to announce that the company has been successful in the tender bidding process in Norway. The company has been notified of winning two national tender contracts in two different therapeutic areas, starting Feb 1, 2022 and running for two years with option to prolong another two years. This means that the health care providers and patients eligible for these specific treatments will have access to our value-added products throughout the tender contract period in Norway. The therapeutic areas in scope for these two treatments are sedation and anti-thrombotic treatment.